The first report of CC-115 in human cancer therapy was in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) harboring ATM deletions/mutations; clinical benefits were observed in 7 out of 8 patients (Table 2) [76]. Here, ATM is linked to B-cell chronic lymphocytic leukemia.